Skip to content
Biotechnology, Property Real Estate

Mould Eradicated! Allied BioServices launches mould remediation service for residential property

Allied BioServices 2 mins read

Sydney 19 July 2023 In a ground-breaking first-to-market initiative, Allied BioServices has launched a revolutionary new mould remediation service which will see the business partner with residential property owners and managers to eliminate harmful mould from homes.

 

The service, which leverages a cutting-edge, long-lasting non-toxic coating technology, responds to the growing incidence of concern among tenants about mould in their homes and aims to eradicate it from residential rental properties.

 

Introducing the program, Allied BioServices’ Vice President, Strategic Partnerships, Dan Ode said, “Mould is a long-standing challenge across Australia, presenting health risks and compromising situations for both landlords and tenants.”

 

“Complaints and requests for elimination of chronic mould are a challenge for Property Managers, especially those with sizeable portfolios under management, particularly in tropical and sub-tropical areas. With the abundance of rain this winter, a warming climate, increased humidity, and more frequent extreme weather, this will only continue. Our service addresses these challenges in a safe and accessible way.”

 

“No Australian should have to live in a property infested with mould,” Mr Ode said, “and by applying our solution, they won’t need to.”

 

The service takes a systematic approach to eradicate mould from Australia’s public and private rental housing stock.

 

The solution is environmentally friendly, nontoxic, and clinically proven to make surfaces hostile to a large range of spores, germs, bacteria, viruses, and COVID-19. The long-lasting, TGA verified product is combined with a specialised surface preparation and application service leveraging state-of-the-art electrostatic sprayers and has been applied, independently tested and proven effective across a wide range of properties.

 

The coating is non-toxic so it is pet friendly and can be applied anytime during the duration of the lease as tenants don’t need to move out for the service to be undertaken.

 

Allied BioServices is taking expressions of interest from those who would like to learn more or book the service. Given the competitive price point and prevalence of damp mould conducive conditions across the east coast of Australia, the company has had strong demand in pre-launch testing of the market for the service.

 

The service is currently available to real estate businesses and property managers across all the Eastern seaboard including the ACT and Victoria.

 

 

ends

  

Interviews available

 

  • Allied BioServices Vice President, Strategic Partnerships, Dan Ode 

 

About Allied BioServices 

Allied BioServices is an Australian company operating across Australia and New Zealand. It provides the world’s best infection control technologies and services to prevent avoidable infection and protect people’s health. Allied BioServices’ technologies and services are guaranteed to deliver proven, high-quality outcomes that are sustainable and eco-friendly. Our technologies and services create safer spaces. 

https://alliedbioservices.com.au/


Key Facts:

Allied BioServices launches new mould remediation service for residential property.

Environmentally friendly, long lasting, non toxic solution that also makes surfaces hostile to spores, germs, bacteria and viruses, including COVID-19.

No need to vacate property for the service to be undertaken.

Available across Australia's Eastern seaboard.

Benefit to Property Managers:

• Protect landlord investment

• Protect tenants

• Decreased vacancy rates – due to clean / protected residence

• Gain increased market share due to unique offering

Benefit to Landlords:

• Protect investment — maintain rental value

• Protect property from serious mould issues

• If rental is fully furnished, protects home contents

• Protect property from further damage.

Benefit to Tenants:

• Minimise risk of mould-associated health issues

• Home is protected from further mould damage

• Are not exposed to highly toxic chemicals

• Pet friendly


Contact details:

Monika Lancucki, Pesel & Carr

Mob: 0413 440 236

Email: [email protected]

 

More from this category

  • Biotechnology
  • 08/12/2025
  • 23:40
Recursion Pharmaceuticals, Inc.

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of untreated FAP patients - who resembled the inclusion criteria of TUPELO - had annualized polyp-burden increase, 10% remained stable, and 3% showed modest decrease—underscoring the disease’s progressive trajectory (n=55)40% of patients (4…

  • Biotechnology
  • 04/12/2025
  • 09:35
Evinco Therapeutics Pty Ltd

Launch of Evinco Therapeutics: A pioneering biotech company advancing immune therapies for Alzheimer’s disease

Evinco Therapeutics is an Australian start-up on a mission to transform the treatment of Alzheimer’s disease and other neuroinflammatory conditions Melbourne, Australia, 4 December 2025 – An exciting chapter in medical innovation begins today with the official launch of Evinco Therapeutics Pty Ltd (“Evinco” or “Company”), a Melbourne-based biotechnology company developing advanced immune-based therapies for neurological disorders under the leadership of CEO and Executive Chair, Prof. Alan Trounson AO. Evinco is a spin-out from Cartherics Pty Ltd (“Cartherics”), allowing Cartherics to focus on its development programs in cancer and endometriosis. Evinco is raising capital to enable proof of concept studies.…

  • Biotechnology
  • 03/12/2025
  • 10:49
4DMedical Limited (ASX:4DX)

4DMedical secures US$10m CTVQ orders in Philips deal

Highlights• Philips will add CT:VQ™ to its North American product catalogue, backed by minimum contractual order commitment of approximately A$15m (US$10m) over two years • CT:VQ™ sales via Philips will be on full commercial terms • Philips to deploy dedicated sales and clinical specialists with CT:VQ™ targets across United States and Canada • Commercial launch announced at a breakfast session at the Radiological Society of North America (RSNA) annual meeting, the largest radiological conference in North America • Given the clinical and logistical advantages of CT:VQ™ over traditional nuclear VQ imaging modalities, 4DMedical expects to displace 100% of all nuclear…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.